足球一世66814

师资队伍


扫描此二维码分享

当前位置: 首页 > 师资队伍 > 正文

于梦

发布时间:2019年02月28日 浏览次数:次

姓名:于梦

职称:副教授,硕士生导师

联系邮箱:yumeng999@smu.edu.cn


学习经历:

2013.09-2016.07 天津大学,药剂学,博士

2011.09-2013.07 天津大学,药剂学,硕士

2007.09-2011.07 广东药科大学,药物制剂,学士


工作经历:

2022.09-2024.09 法国巴黎高等师范足球一世66814,访问学者

2018.12-至今 南方医科大学足球一世66814,副教授

2016.07-2018.11 中山大学材料科学与工程足球一世66814,特聘副研究员


研究方向:

1. 内外源刺激响应型脂质体、高分子纳米载体研究;

2. 外源刺激(光、电、超声、X射线等)诱导肿瘤动力学治疗其作用机制研究;

3. 病灶微环境(炎性、菌群、代谢)调控体系抑制病程进展的研究。


学术任职:

1. 2020.12-至今 广东省精准医学应用学会分子影像分会,常务委员

2. 2019.09-至今 Asian Journal of Pharmaceutical Sciences,青年编委

3. 2019.07-至今 Chinese Chemical Letters,青年编委

4. 2019.03-至今 广东省生物医学工程学会,会员

5. 2017.09-至今 中国生物材料学会,会员


主要科研课题:

1、广东省自然科学基金-青年提升项目,非氧依赖的电动力学-免疫级联疗法治疗乏氧耐药肿瘤的研究,2023.01-2025.12,主持。

2、南方医科大学优青培育项目,智能响应脂质体在肿瘤微环境调控及协同治疗上的应用研究,2020.04-2022.04,主持。

3、国家自然科学基金青年项目,81701817,PFH脂质体用于改善缺氧治疗抗性和超声成像的研究,2018.01-2020.12,主持。

4、广东省自然科学基金-面上项目,2019A1515011498,基于“级联效应”的外源诱导响应纳米药物抗肿瘤研究,2019.10-2022.09,主持。

5、广州市基础与应用基础研究项目,202201011130280065,光控智能响应脂质体用于耐药乳腺癌精准治疗的研究,2022.04-2024.03,主持。

6、南方医科大学高层次人才引进科研启动项目, 内外源刺激响应纳米载体在肿瘤治疗上的应用研究,2019.01-2021.12,主持。

7、广东省口腔医学重点实验室(中山大学)开放课题基金,KF2019120102,低剂量放疗敏感脂质体用于口腔癌免疫协同治疗研究,2020.01-2021.12,主持。

8、教育部中央高校基本科研业务费,17lgpy09,Ce6@MnO2@Au载体系统用于增强缺氧环境下PDT治疗效果的研究,2017.1-2018.11,主持。

9、佛山市“登峰计划”项目,佛山市乳腺癌临床耐药患者精准化治疗平台建设,2020.10-2023.10,参与。

10、东莞市重点项目,T 细胞靶向募集脂质体凝胶用于乳腺癌免疫联合治疗的研究,2021.10-2024.09,参与。


代表性成果:

1SCI论文

[1] Li L#, He SH#, Liao BY, Lin HM, Wang MC, Hu B, Lan XY, Shu ZL, Zhang C*, Yu M*, Zou ZW*. Orally administrated hydrogel harnessing intratumoral microbiome and microbiota-related immune responses for potentiated colorectal cancer treatment. Research, 2024. (IF: 11.0)

[2] Xu QQ, Ban XH, Yang LJ, Chen YR, Zhang F, Wang Y, Cao P*, Yu M*, Duan XH*. MRI-visualized PTT/CDT for breast cancer ablation and distant metastasis prevention. Applied Materials Today, 2024, 36: 102059. (IF: 8.3)

[3] Wang YH#, Zhang BC#, Xi QY, Chen CJ, Wang ZJ, Li FZ, Wang ST, Yang W, Liang XJ*, Yu ZQ*, Yu M*. Gemcitabine nano-prodrug reprograms intratumoral metabolism and alleviates immunosuppression for hepatocellular carcinoma therapy. Nano Today, 2023, 53: 102009. (IF: 17.4)

[4] Zhu MY#, Fan HN#, Deng JL#, Jiang K, Liao JB, Zhang XY, Chen Y*, Yu M*, Peng ZW*. BMI1 silencing liposomes suppress post-radiotherapy cancer stemness against radioresistant hepatocellular carcinoma. ACS Nano, 2023, 17(23): 23405-23421. (IF: 17.0)

[5] Feng ZZ#, Chen G#, Zhong M, Lin L, Mai ZY, Tang Y, Chen GM, Ma W, Li G, Yang YY*, Yu ZQ*, Yu M*. An acid-responsive MOF nanomedicine for augmented anti-tumor immunotherapy via a metal ion interference-mediated pyroptotic pathway. Biomaterials, 2023, 302: 122333. (IF: 14.0)

[6] Lin HM#, Xu Q#, Zhang F#, Wu HL, Hu B, Chen GM, Ban XH*, Duan XH*, Yu M*. Self-assembled carrier-free nanomedicine suppresses tumor stemness to overcome the acquired drug-resistance of hepatocellular carcinoma. Chemical Engineering Journal, 2023, 474: 145555. (IF: 15.1)

[7] Tang YH#, Shu ZL#, Zhu MY#, Li SP, Ling YY, Fu YZ, Hu ZL, Wang JL, Yang ZY, Liao JB, Xu L, Yu M*, Peng ZW*. Size-tunable nanoregulator-based radiofrequency ablation suppresses MDSCs and their compensatory immune evasion in hepatocellular carcinoma. Advanced Healthcare Materials, 2023, 2302013. (IF: 10.0)

[8] Zhuang XD#, Li B#, Liu XY, Fan TT, Lan XY, Wang XY*, Yu M*. The colorectal cancer-specific microbiome regulation and immune response activation via an artificial biomimetic nanovaccine. Chemical Engineering Journal, 2023, 461: 141982. (IF: 15.1)

[9] Lan XY#, Liang JG#, Wen CR, Quan XL, Lin HM, Xu QQ, Chen PX, Yao GY*, Zhou D*, Yu M*. Photo-manipulated polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy. Chinese Chemical Letters, 2023, DOI: 10.1016/j.cclet.2023.108616. (IF: 9.1)

[10] Xu QQ#, Lan XY#, Lin HM, Xi QY, Wang MC, Quan XL, Yao GY, Yu ZQ, Wang YX*, Yu M*. Tumor microenvironment-regulating nanomedicine design to fight multi-drug resistant tumors. WIREs Nanomed Nanobiotechnol, DOI: 10.1002/wnan.1842.

[11] Chen G#, Xu Q#, Feng ZZ, Xu QQ, Zhang XH, Yang YY, Zhang YX, Liang XJ*, Yu ZQ*, Yu M*. Glutamine antagonist synergizes with electrodynamic therapy to induce tumor regression and systemic antitumor immunity. ACS Nano, 2022, 16(1): 951-962. (IF: 17.0)

[12] Zhou Y, Wang SY, Liang XY, Heger Z, Xu M, Lu Q, Yu M*, Adam V*, Li N*. Turning Hot into Cold: Immune Microenvironment Reshaping for Atherosclerosis Attenuation Based on pH-Responsive shSiglec-1 Delivery System. ACS Nano, 2022, 16, 10517-10533. (IF: 17.0)

[13] Wang YH#, Wang ZJ#, Jia F, Xu Q, Shu ZL, Deng JL, Li AM*, Yu M*, Yu ZQ*. CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment. Bioactive Materials, 2022, 17, 147-161. (IF: 18.9)

[14] Xu Q#, Chen G#, Chen GM, Wu HL, Yang YY, Mai ZY, Sun R, Luan P, Guo CW, Yu M*, Peng ZW*, Yu ZQ*. NO-dependent vasodilation and deep tumor penetration for cascade amplified antitumor performance. Journal of Controlled Release, 2022, 347: 389-399. (IF: 10.8)

[15] Lin HM#, Shi SW#, Lan XY, Quan XL, Xu QQ, Yao GY, Liu J, Shuai XT, Wang C*, Li X*, Yu M*. Scaffold 3D-printed from metallic nanoparticles-containing ink simultaneously eradicates tumor and repairs tumor-associated bone defects. Small Methods, 2021, 2100536. (IF: 12.4)

[16] Yang YY#, Liu X#, Ma W, Xu Q, Chen G, Wang YF, Xiao HH, Li N, Liang XJ*, Yu M*, Yu ZQ*. Light-activatable liposomes for repetitive on-demand drug release and immunopotentiation in hypoxic tumor therapy. Biomaterials, 2021, 265: 120456. (IF: 14.0)

[17] Yu L#, Wang ZJ#, Mo ZM, Zou BH, Yang YY, Sun R, Ma W, Yu M*, Zhang SJ*, Yu ZQ*. Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy. Acta Pharmaceutica Sinica B, 2021, 7(11):2004-2015. (IF: 14.5)

[18] Chen G#, Yang YY#, Xu Q, Ling MJ, Lin HM, Ma W, Sun R, Xu YC, Liu X, Li N, Yu ZQ*, Yu M*. Self-Amplification of tumor oxidative stress with degradable metallic complexes for synergistic cascade tumor therapy. Nano Letters, 2020, 20(11): 8141-8150. (IF: 10.8)

[19] Li W, Wang SY, Ren CC, Liu P, Lu QL, Yang LF, Song YL, Xu M, Tan FP, Yu M*, Li N*. Exo/endogenous dual-augmented chemodynamic therapy based on bio-reducible and bio-breakable copper(II)-based truncated octahedron. Chemical Engineering Journal, 2020, 396: 125280. (IF: 15.1)

[20] Liu ZP, Xie Y, Xiong Y, Liu SL, Qiu C, Zhu ZH, Mao H, Yu M*, Wang XY*. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. Cancer Letters, 2020, 469(28): 173-185. (IF: 9.7)

[21] Yu M#, Duan XH#, Cai YJ, Zhang F, Jiang SQ, Han SS, Shen J*, Shuai XT*. Multifunctional nanoregulator reshapes immune microenvironment and enhances immune memory for tumor immunotherapy. Advanced Science, 2019, 6: 1900037. (IF: 15.1)

[22] Yu M, Xu XL, Cai YJ, Zou LY, Shuai XT*. Perfluorohexane-cored nanodroplets for stimulations-responsive ultrasonography and O2-potentiated photodynamic therapy. Biomaterials, 2018, 175: 61-71. (IF: 14.0)

2. 专著

[1] Yu M, Li N, Shuai XT. “Chapter 4: Multi-phototherapy based on combined use of photosensitizers and photothermal agents” in “Photosensitizers: Types, Uses and Selected Research”, Nova Science Publishers, 2016.

[2] 《生物医用高分子材料》,科学出版社,2021,参编。

3. 专利

[1] 于梦,林慧敏,王翀,李翔,史善伟,李政诗。具有抗肿瘤和组织修复作用的双功能支架和制备方法。ZL202110306609.1(已授权)。

[2] 喻志强,杨媛媛,于梦,于玲,马文,邹斌华,陈归,孙锐。光敏脂质体及其应用。ZL202010673715.9(已授权)。

[3] 姚广裕,于梦,林周盛,黄泽,兰新月,廖明楷,崔光曼,林嘉英,叶长生。双腔注射器。ZL202121957903.0(已授权)。

[4] 陈帅君,于超生,于梦,权小龙,许熠铭,胡学勇。一种光响应可促渗抗肿瘤纳米粒子及其制备方法和应用。ZL202311022572.5(已授权)。

[5] 于梦,姚广裕,兰新月,文楚然,权小龙,林慧敏。一种光控释药可注射脂质体凝胶的制备及应用。CN202310492429.6(审批中)。

[6] 于梦,邹兆伟,李磊,何首华,兰新月,胡犇。一种能够调控肠道及瘤内菌群的口服水凝胶的制备及应用。CN202310891066.3(审批中)。

[7] 于梦,姚广裕,兰新月,王永霞,林慧敏,崔光曼,权小龙。一种可调控肿瘤内菌群的纳米药物及制备方法和应用。CN 202311344646.7(审批中)。

上一条:徐伟

下一条:田立文

足球一世66814 - 搜狗指南